Marcelo Bigal
Vermögen: 413 270 $ am 31.05.2026
Vermögen: 413 270 $ am 31.05.2026
Currently, Marcelo Bigal is President, Chief Executive Officer & Director at Ventus Therapeutics U.S., Inc. and Ventus Therapeutics, Inc., Independent Director at Pacira Biosciences, Inc., and Director at Santa Ana Bio, Inc. Formerly, Dr. Bigal was Director at CODA Biotherapeutics, Inc. from 2019 to 2022, Chief Medical Officer & Head-Specialty Clinical at Teva Pharmaceutical Industries Ltd. from 2017 to 2018, Chief Medical Officer at Labrys Biologics, Inc., and Venture Partner at Versant Venture Management LLC.
Education includes a doctorate from Faculdade de Direito da Universidade de São Paulo.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PACIRA BIOSCIENCES, INC. 0,05 % | 10.06.2026 | 17.798 ( 0,05 % ) | 413 270 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| PACIRA BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 10.10.2023 |
Ventus Therapeutics, Inc.
Ventus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics | Vorstandsvorsitzender | 01.05.2019 |
Ventus Therapeutics U.S., Inc.
Ventus Therapeutics U.S., Inc. Medical DistributorsDistribution Services Wholesales drugs | Vorstandsvorsitzender | - |
Santa Ana Bio, Inc.
Santa Ana Bio, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which focuses on precision immunology for autoimmune diseases | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Private Equity Investor | 01.09.2023 |
CODA Biotherapeutics, Inc.
CODA Biotherapeutics, Inc. Medical SpecialtiesHealth Technology Develops chemo genetic neuromodulation platform for the treatment of severe neurological disorders | Direktor/Vorstandsmitglied | 01.12.2022 |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2018 |
Labrys Biologics, Inc.
Labrys Biologics, Inc. BiotechnologyHealth Technology Provides biotechnology services | Technik-/Wissenschafts-/F&E-Leiter | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 9 |
|---|---|
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients | Health Technology |
Labrys Biologics, Inc.
Labrys Biologics, Inc. BiotechnologyHealth Technology Provides biotechnology services | Health Technology |
Pacira Biosciences, Inc.
Pacira Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures injectable therapeutic products | Health Technology |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Finance |
Faculdade de Direito da Universidade de São Paulo
Faculdade de Direito da Universidade de São Paulo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CODA Biotherapeutics, Inc.
CODA Biotherapeutics, Inc. Medical SpecialtiesHealth Technology Develops chemo genetic neuromodulation platform for the treatment of severe neurological disorders | Health Technology |
Ventus Therapeutics, Inc.
Ventus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics | Health Technology |
Ventus Therapeutics U.S., Inc.
Ventus Therapeutics U.S., Inc. Medical DistributorsDistribution Services Wholesales drugs | Distribution Services |
Santa Ana Bio, Inc.
Santa Ana Bio, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which focuses on precision immunology for autoimmune diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen